Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $10.00 price target on Savara (NASDAQ: SVRA).

The analyst commented, "We think Molbreevi’s approval is highly likely (90% POS), as regulatory momentum continues to build with the EMA having initiated its review of the Molbreevi MAA and a decision expected in 1Q27. Earlier this month, SVRA submitted the MAA for Molbreevi to the U.K.’s MHRA. In the U.S., Molbreevi’s BLA is under FDA Priority Review with a PDUFA date of August 22, 2026. Commercially, our most recent pulmonologist survey indicated expected ~60% utilization rate for Molbreevi, supporting a blockbuster U.S. opportunity. We model peak U.S. sales of approximately $1B in 2032 and EU peak sales of ~$550M."

For an analyst ratings summary and ratings history on Savara click here. For more ratings news on Savara click here.

Shares of Savara closed at $5.05 yesterday.